Effect of omega 3 in the prevention of 30-days major adverse cardiovascular events following Carotid Stenting
Not Applicable
Completed
- Conditions
- Cerebrovascular diseases.Occlusion and stenosis of carotid artery
- Registration Number
- IRCT2017011120441N6
- Lead Sponsor
- Shiraz University of Medical Sciences, Vice Chancellor of Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients undergoing carotid stenting (more than 50% stenosis of the internal carotid artery in symptomatic patients, or 70% stenosis in asymptomatic patients); The ages of 18 to 80 years
Exclusion criteria: Unsatisfactory carotid artery stenting; Intraluminal thrombus over the stenosis; pretreatment with glycoprotein IIb/IIIa antagonists or bivalirudin; Active bleeding; Sensitivity or tolerance to aspirin or Clopidogrel or omega-3; Sever adverse effects to drugs; Percutaneous
intervention or surgery less than 30 days
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Major adverse cardiovascular events (MACE). Timepoint: 30 days after carotid stenting. Method of measurement: Following patients by phone.
- Secondary Outcome Measures
Name Time Method Stroke. Timepoint: 24-hrs following carotid stenting. Method of measurement: MRI.